Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederalnylampharmaceuticalsinc.gcs-web.com
Alnylam Pharmaceuticals, Inc. News Releases
Get the latest updates from Alnylam Pharmaceuticals, Inc. News Releases directly as they happen.
Follow now 37 followers
Latest posts
Last updated 2 days ago
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
2 days ago
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 12, 2025-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the...
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
9 days ago
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 5, 2025-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the...
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
13 days ago
− Achieved First Quarter 2025 Global Net Product Revenues of $469 Million...
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
16 days ago
− Recommended Approval Based on the Pivotal HELIOS-B Phase 3 Study in...
Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results
27 days ago
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 17, 2025-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the...
Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference
about 1 month ago
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 1, 2025-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the...
Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025
about 2 months ago
− New Data Follow Recent U.S. FDA Approval of AMVUTTRA ® (vutrisiran)...
FDA Approves Qfitlia™ (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B
about 2 months ago
– Qfitlia Becomes the Sixth Alnylam-Discovered RNAi Therapeutic Approved by U.S. FDA...
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
about 2 months ago
− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the...
Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum
2 months ago
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 11, 2025-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the...
Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary
2 months ago
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 5, 2025-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the...
Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day
3 months ago
– Showcases multiple potentially transformative near- and mid-stage therapies in ATTR amyloidosis...